-imod
Drugs that adjust the immune response.
- Drugs ending in -imod: 69
- Approved somewhere: 7
- With a US drug page: 6
- Stem
- -imod
- Class
- Drugs that adjust the immune response
Approved and clinical-stage drugs in ChEMBL whose names ending in -imod or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Efgartigimod alfa | Approved | FCGRT | IgG receptor FcRn large subunit p51 antagonist |
| Fingolimod | Approved | Sphingosine 1-phosphate receptor | Sphingosine 1-phosphate receptor agonist |
| Imiquimod | Approved | TLR7 | Toll-like receptor 7 agonist |
| Ozanimod | Approved | S1PR1, S1PR5 | Sphingosine 1-phosphate receptor Edg-1 modulator |
| Ponesimod | Approved | S1PR1 | Sphingosine 1-phosphate receptor Edg-1 agonist |
| Siponimod | Approved | S1PR1 | Sphingosine 1-phosphate receptor Edg-1 agonist |
| Etrasimod | Approved | S1PR1, S1PR4, S1PR5 | Sphingosine 1-phosphate receptor Edg-1 agonist |
| Blisibimod | Phase 3 | TNFSF13B | Tumor necrosis factor ligand superfamily member 13B inhibitor |
| Cenerimod | Phase 3 | S1PR1 | Sphingosine 1-phosphate receptor Edg-1 modulator |
| Forigerimod | Phase 3 | HSPA8 | Heat shock cognate 71 kDa protein inhibitor |
| Iguratimod | Phase 3 | MIF, TRAF3IP2, PTGS2 | Macrophage migration inhibitory factor inhibitor |
| Laquinimod | Phase 3 | — | — |
| Obefazimod | Phase 3 | NCBP1, NCBP2 | Cap binding complex modulator |
| Tasquinimod | Phase 3 | — | — |
| Amiselimod | Phase 2 | Sphingosine 1-phosphate receptor | Sphingosine 1-phosphate receptor modulator |
| Amlisimod | Phase 2 | — | — |
| Apilimod | Phase 2 | PIKFYVE | 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor |
| Atiprimod | Phase 2 | — | — |
| Cridanimod | Phase 2 | — | — |
| Epetirimod | Phase 2 | — | — |
| Golotimod | Phase 2 | — | — |
| Icanbelimod | Phase 2 | — | — |
| Indoximod | Phase 2 | mTORC1 | mTORC1 activator |
| Limaresiquimod | Phase 2 | — | — |
| Lirodegimod | Phase 2 | — | — |
| Mocravimod | Phase 2 | S1PR1 | Sphingosine 1-phosphate receptor Edg-1 agonist |
| Mosedipimod | Phase 2 | — | — |
| Orilotimod | Phase 2 | — | — |
| Paquinimod | Phase 2 | — | — |
| Pidotimod | Phase 2 | — | — |
| Reltecimod | Phase 2 | — | — |
| Resiquimod | Phase 2 | TLR8, TLR7 | Toll-like receptor 8 agonist |
| Tamuzimod | Phase 2 | — | — |
| Vonifimod | Phase 2 | — | — |
| Alintegimod | Phase 1 | — | — |
| Bevifimod | Phase 1 | — | — |
| Defoslimod | Phase 1 | — | — |
| Efizonerimod alfa | Phase 1 | — | — |
| Eftilagimod alfa | Phase 1 | LAG3 | Lymphocyte activation gene 3 protein vaccine antigen |
| Navoximod | Phase 1 | — | — |
| Udifitimod | Phase 1 | — | — |
| Losmapimod | Phase 3 | MAPK14, MAPK11 | MAP kinase p38 alpha inhibitor |
| Acumapimod | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Bentamapimod | Phase 2 | c-Jun N-terminal kinase, JNK | c-Jun N-terminal kinase, JNK inhibitor |
| Dilmapimod | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Doramapimod | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Neflamapimod | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Semapimod | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Talmapimod | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Emprumapimod | Phase 1 | — | — |
| Balamapimod | — | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Pamapimod | — | MAPK14 | MAP kinase p38 alpha inhibitor |
| Agatolimod | Phase 3 | TLR9 | Toll-like receptor 9 agonist |
| Cobitolimod | Phase 3 | TLR9 | Toll-like receptor 9 agonist |
| Rintatolimod | Phase 3 | TLR3 | Toll-like receptor 3 agonist |
| Tilsotolimod | Phase 3 | TLR9 | Toll-like receptor 9 agonist |
| Entolimod | Phase 2 | TLR5 | Toll-like receptor 5 agonist |
| Lefitolimod | Phase 2 | TLR9 | Toll-like receptor 9 agonist |
| Motolimod | Phase 2 | TLR8 | Toll-like receptor 8 agonist |
| Ruzotolimod | Phase 2 | — | — |
| Selgantolimod | Phase 2 | TLR8 | Toll-like receptor 8 agonist |
| Tilsotolimod sodium | Phase 2 | TLR9 | Toll-like receptor 9 agonist |
| Vesatolimod | Phase 2 | TLR7 | Toll-like receptor 7 activator |
| Vidutolimod | Phase 2 | — | — |
| Cobitolimod sodium | Phase 1 | — | — |
| Guretolimod | Phase 1 | — | — |
| Nelitolimod | Phase 1 | — | — |
| Nelitolimod sodium | Phase 1 | — | — |
| Telratolimod | Phase 1 | TLR8, TLR7 | Toll-like receptor 8 agonist |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO